The price of Exelixis shares has slipped to $4.83 (a 7.8% change) on heavy trading volume. Approximately 6.5 million shares have changed hands today vs. average 30-day volume of 2.2 million shares. Unusually high volume can signify a potential turning point or validate a breakout.
In the past 52 weeks, Exelixis share prices have been bracketed by a low of $3.94 and a high of $12.82 and are now at $4.83, 23% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.2% while the 200-day MA has slid 0.2%.
There is potential upside of 18.0% for shares of Exelixis based on a current price of $4.83 and an average consensus analyst price target of $5.70. The stock should run into initial resistance at its 50-day moving average (MA) of $4.93 and subsequent resistance at its 200-day MA of $5.11.
Exelixis, Inc. is involved in comparative genomics and model system genetics. The Company's technologies focus on the identification and validation of novel screening targets and proteins and their function for the pharmaceutical, diagnostic, agricultural, and animal health industries. Exelixis' areas of research include CNS, inflammation, oncology, and metabolic disease.